Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LadRx Corporation (LADX)
Los Angeles, CA, US
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumor. Its lead candidates comprising LADRs 7, 8, 9, and 10 with novel derivatives of the auristatin and maytansinoid drug targeting tumors; and aldoxorubicin, which is in phase II clinical development for the treatment of pancreatic cancer. In addition, the company develops albumin companion diagnostic (ACDx) to identify patients with cancer that benefits from treatment with the four LADR lead candidates. The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. The company was incorporated in 1985 and is headquartered in Los Angeles, California.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -4.55% | +950.00% | +5.00% | -19.23% | +950.00% | -93.75% | -98.69% | -99.91% | -99.99% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-472,289.7% Q1'25: -481.6% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'25: +122.9% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%+1.4% ★ Q1'25: +0.0% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'25: 0.00× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
|---|---|---|---|---|---|
| Revenue |
200.0K
est: 100.0K (+100.0%)
|
250.0K
est: 250.0K (+0.0%)
|
—
est: 28.26M (-100.0%)
|
—
est: 67.61M (-100.0%)
|
—
est: 113.28M (-100.0%)
|
| EBITDA |
-47.48M
|
-7.33M
|
-7.50M
|
-6.80M
|
-13.16M
|
| EBIT |
-48.02M
|
-7.36M
|
-7.52M
|
-6.83M
|
-13.18M
|
| Net Income |
-50.77M
est: -207.94M (+75.6%)
|
-12.71M
est: -20.30M (+37.4%)
|
-7.16M
est: -11.88M (+39.7%)
|
-6.70M
est: -14.85M (+54.9%)
|
-13.18M
est: 101.00M (-113.0%)
|
| SGA |
15.99M
|
8.08M
|
7.44M
|
6.00M
|
5.97M
|
| EPS |
-378.00
est: -420.00 (+10.0%)
|
-41.08
est: -41.00 (-0.2%)
|
-2,153.42
est: -24.00 (-8,872.6%)
|
-19.34
est: -30.00 (+35.5%)
|
-35.52
est: 204.00 (-117.4%)
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-15 | Snowdy Stephen | Officer | A-Award | A | Stock Option (Right to Buy) | 25,000 | 1.83 | 45.8K | 25,000 | — | ↗ |
| 2024-01-15 | Simpson Jennifer K. | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.83 | 9.2K | 5,000 | — | ↗ |
| 2024-01-15 | Claiborne Cary J | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.83 | 9.2K | 5,000 | — | ↗ |
| 2024-01-15 | Caldwell Joel K | Director | A-Award | A | Stock Option (Right to Buy) | 5,000 | 1.83 | 9.2K | 5,000 | — | ↗ |
| 2024-01-15 | CALOZ JOHN Y | Officer | A-Award | A | Stock Option (Right to Buy) | 15,000 | 1.83 | 27.5K | 15,000 | — | ↗ |
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Stephen Snowdy, Ph.D. Chief Executive Officer | 520.0K | 25.0K | — | — | — | — | 545.0K | 0.00% | ↗ |
| 2 | 2023 | John Y. Caloz Chief Financial Officer, Treasurer and Senior Vice President | 416.0K | — | — | — | — | — | 416.0K | 0.00% | ↗ |
| 3 | 2022 | Stephen Snowdy, Ph.D. Chief Executive Officer | 488.1K | 75.0K | — | — | — | — | 563.1K | 0.00% | ↗ |
| 4 | 2022 | John Y. Caloz Chief Financial Officer, Treasurer and Senior Vice President | 400.0K | 100.0K | — | — | — | — | 500.0K | 0.00% | ↗ |
| 5 | 2021 | Steven A. Kriegsman Former Chief Executive Officer | 850.0K | 150.0K | — | — | — | 6.01M | 7.01M | 0.00% | ↗ |
| 6 | 2021 | John Y. Caloz Chief Financial Officer, Treasurer and Senior Vice President | 400.0K | 100.0K | — | — | — | — | 500.0K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| John Y. Caloz | Treasurer, Senior Vice President & Corporate Secretary | 428.5K | male |
| Molly Carey Poarch | Global & U.S. Head of Corporation Communications | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LADX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
